U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Ca.HO4P
Molecular Weight 136.057
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANHYDROUS DIBASIC CALCIUM PHOSPHATE

SMILES

[Ca++].OP([O-])([O-])=O

InChI

InChIKey=FUFJGUQYACFECW-UHFFFAOYSA-L
InChI=1S/Ca.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+2;/p-2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

1921
1467
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
504
Unknown

Approved Use

Unknown
Palliative
Phase I
428
Unknown

Approved Use

Unknown
Palliative
Phase I
428
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
1,25 dihydroxyvitamin D3 enhances the calcium response of keratinocytes.
1999 Feb
Aluminum is a weak agonist for the calcium-sensing receptor.
1999 May
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.
1999 Sep 20
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V.
2000 Feb 11
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells.
2000 Jun
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.
2000 Oct 15
Chemokines induce eosinophil degranulation through CCR-3.
2000 Sep
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.
2000 Sep
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.
2001 Aug
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.
2001 Jul
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.
2001 Mar 15
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.
2001 Mar 2
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses.
2001 Mar 27
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.
2001 Nov 1
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.
2001 Nov 30
Familial intrahepatic cholestasis 1: studies of localization and function.
2001 Oct
Microarray analysis of differential gene expression in lead-exposed astrocytes.
2001 Oct 1
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.
2002 Sep 6
Henri Moissan: winner of the Nobel Prize for Chemistry 1906.
2006 Oct 20
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.
2015 Aug 12
Lactose behaviour in the presence of lactic acid and calcium.
2016 Aug
Patents

Patents

03966773
137
03974176
93
03981818
91
04008309
69
04028407
67
04041173
67
04042702
91
04058507
67
04063023
67
06485737
67
06497902
67
08637538
67
20090030026
67
20130174651
67
JP2017071731
67
US2143359
67

Sample Use Guides

In Vivo Use Guide
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
II  
Preferred Name English
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
USP  
Common Name English
CALCIUM PHOSPHATE DIBASIC
WHO-DD  
Common Name English
CALCIUM PHOSPHATE (DIBASIC)
Common Name English
CALCIUM HYDROGEN PHOSPHATE ANHYDROUS
Common Name English
CALCIUM HYDROGEN ORTHOPHOSPHATE
Systematic Name English
DICALCIUM PHOSPHATE
INCI  
INCI  
Official Name English
INS-341(II)
Code English
CALCII HYDROGENOPHOSPHAS [WHO-IP LATIN]
Common Name English
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS [II]
Common Name English
CALCIUM PHOSPHATE, DIBASIC
HSDB   MI  
Common Name English
CALCIUM PHOSPHATE,DIBASIC [VANDF]
Common Name English
CALCIUM PHOSPHATE, DIBASIC ANHYDROUS
Common Name English
PHOSPHORUS (AS DICALCIUM PHOSPHATE) [VANDF]
Common Name English
CALCIUM MONOHYDROGEN PHOSPHATE
Systematic Name English
PHOSPHORUS (AS CALCIUM PHOSPHATE,DIBASIC) [VANDF]
Common Name English
CALCIUM PHOSPHATE, DIBASIC [HSDB]
Common Name English
DICALCIUM ORTHOPHOSPHATE
Systematic Name English
PHOSPHORUS (AS DICALCIUM PHOSPHATE)
VANDF  
Common Name English
DIBASIC CALCIUM PHOSPHATE ANHYDROUS
Common Name English
Calcium phosphate dibasic [WHO-DD]
Common Name English
CALCIUM PHOSPHATE, DIBASIC [MI]
Common Name English
CALCIUM HYDROGEN MONOPHOSPHATE
Systematic Name English
ANHYDROUS DIBASIC CALCIUM PHOSPHATE [USP MONOGRAPH]
Common Name English
DIBASIC CALCIUM PHOSPHATE
Common Name English
CALCIUM (CALCIUM PHOSPHATE (DIBASIC))
Common Name English
CALCIUM HYDROGEN PHOSPHATE [EP MONOGRAPH]
Common Name English
CALCIUM (AS PHOSPHATE,DIBASIC) [VANDF]
Common Name English
DICALCIUM PHOSPHATE [INCI]
Common Name English
INS NO.341(II)
Code English
CALCIUM HYDROGEN PHOSPHATE, ANHYDROUS [WHO-IP]
Common Name English
CALCIUM PHOSPHATE (1:1) [WHO-IP]
Common Name English
E-341(II)
Code English
ANHYDROUS DIBASIC CALCIUM PHOSPHATE [JAN]
Common Name English
CALCIUM HYDROGEN PHOSPHATE (ANHYDROUS)
Common Name English
PHOSPHORIC ACID, CALCIUM SALT (1:1)
Common Name English
CALCIUM HYDROGEN PHOSPHATE
Systematic Name English
SECONDARY CALCIUM PHOSPHATE
Common Name English
CALCIUM PHOSPHATE (1:1)
WHO-IP  
Systematic Name English
Classification Tree Code System Code
CODEX ALIMENTARIUS (GSFA) INS-341(II)
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
JECFA EVALUATION INS-341(II)
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
Code System Code Type Description
PUBCHEM
24441
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
RXCUI
47627
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
SMS_ID
100000087353
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
DAILYMED
L11K75P92J
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
WIKIPEDIA
DICALCIUM PHOSPHATE
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY Description: A white or almost white powder; odourless. Solubility: Practically insoluble in cold water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Tablet and capsule diluent. Storage: Calcium hydrogen phosphate should be kept in a well-closed container. Labelling: The designation on the container of Calcium hydrogen phosphate should state whether it is the dihydrate or the anhydrous form. Requirement: Calcium hydrogen phosphate contains not less than 30.9% and not more than the equivalent of 31.7% of calcium, Ca, calculated with reference to the ignited substance.
FDA UNII
L11K75P92J
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
DRUG BANK
DBSALT002430
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
CHEBI
32596
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
CHEBI
4496
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
NCI_THESAURUS
C77523
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
MERCK INDEX
m2964
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2107567
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
ECHA (EC/EINECS)
231-826-1
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
HSDB
992
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
EPA CompTox
DTXSID20872529
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
CONCEPT Dietary Supplement
EVMPD
SUB16368MIG
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
RXCUI
253163
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
ALTERNATIVE
EVMPD
SUB11772MIG
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
CAS
7757-93-9
Created by admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of CALCIUM CATION
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966